09 May 2025
6m
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.